[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitätsklinikum Hamburg-Eppendorf\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":663},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,62,0,25,[9,45,69,101,129,153,180,206,235,257,289,319,338,361,385,414,446,474,490,514,544,570,598,620,643],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100564767",false,"NCT06633458","Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality and Treatment Outcome","Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality as a Predictor of Treatment Outcome","Inclusion Criteria:\n\n* Admission to inpatient care unit of the adolescent psychiatry at the University Medical Center Hamburg-Eppendorf.\n\nExclusion Criteria:\n\n* Severe symptom burden at admission\n* Lack of knowledge of the German language.","ALL","14 Years","17 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","The quality of parent-adolescent communication has been found to be associated with adolescent mental health. However, little is known about the association of parent-adolescent communication and adolescent mental health in the context of psychiatry inpatient treatment.\n\nThis study aims to find out whether self-reported parent-adolescent communication quality at the time of admission to psychiatry predicts the treatment outcome in terms of symptom reduction 6 months later in an adolescent inpatient sample. It also aims to track changes in adolescent self-reported communication quality in the course of inpatient treatment and afterwards (2, 4 and 6 months after admission) to see whether improvement predicts treatment outcome, with treatment outcome being defined as symptom reduction to baseline. As a secondary endpoint, it will be assessed whether a placement of the adolescent outside the family was considered during treatment and whether self-reported communication quality at the time of admission predicts the consideration of placement outside the family.",[25,26,27],"Mental Disorder in Adolescence","Depression in Adolescence","Anxiety",[29,30,31],"mental health","adolescence","communication","RECRUITING","2026-06-28",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2024-07-08",{"date":40,"type":21},"2027-10-30",{"name":42,"class":43},"Universitätsklinikum Hamburg-Eppendorf","OTHER",1,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100427656","NCT04848844","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R): A Global Register to Investigate Factors Associated With Morbidity and Mortality in Adult Patients With Congenital Heart Disease (ACHD) on the Waiting List for Heart or Heart\u002FLung Transplantation","ARTORIA-R","Inclusion Criteria:\n\n1. The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years\n2. The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD\n3. Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation\n4. Transfer of anonymised data\n5. The institution\u002Forganization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions\n\nExclusion Criteria:\n\na. The patient is listed for a second heart transplantation (retransplantation)","18 Years",{"count":54,"type":21},2000,"30 Years","Advances in surgical and medical care have led to improved outcomes in patients with congenital heart disease (CHD). As a consequence, the majority of patients nowadays survives to adulthood (adults with CHD, that is, adult CHD \\[ACHD\\]) with good quality of life. Despite the surgical success, the morbidity and mortality of ACHD is higher than in the general population and is linked to the development of heart failure (HF) in adulthood.\n\nHF occurs in approximately 25% of patients with ACHD, even in those patients in whom the congenital mal-formation has been corrected successfully in childhood. The time course and presentation are heterogeneous owing to variable congenital malformation and limitation of treatment options. ACHD with an anatomic right ventricle as the systemic ventricle (e.g., atrial switch operation in patients with transposition of the great arteries \\[TGAs\\]) and those with a functional single ventricle (e.g., Fontan circulation) appear to be at higher risk of developing HF. Young age at initial corrective surgery-often in the first 2 years of life-and lack of specific medical therapies can contribute to a high and early demand for heart transplantation in patients with ACHD.",[58,59,60,61,62],"Congenital Heart Disease","Heart Failure","Transplant; Complication, Failure","Arrythmia","Ventricular Dysfunction",{"date":35,"type":36},{"date":65,"type":36},"2020-09-02",{"date":67,"type":21},"2030-07-30",{"name":42,"class":43},{"id":70,"slug":4,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100634338","NCT07538388","Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension","Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension in High-Risk Non-Cardiac Surgery Patients - The Multicenter INDUCT Trial (INDUCT-Multi)","INDUCT-Multi","Inclusion Criteria:\n\nWe will include consenting patients ≥45 years scheduled for elective non-cardiac surgery under general anesthesia with planned continuous intra-arterial blood pressure monitoring with a radial arterial catheter and with at least two of the following risk criteria for developing acute kidney injury:\n\n* Age ≥65 years\n* ASA physical status III or IV\n* Chronic arterial hypertension\n* Diabetes mellitus requiring medication\n* Intra-abdominal surgery\n* Preoperative renal insufficiency (serum creatinine ≥1.2 mg\u002FdL)\n\nExclusion Criteria:\n\n* Pregnancy\n* Cardiac arrhythmia\n* History of intracranial hemorrhage or intracranial aneurysm\n* Clinical indication for continuous norepinephrine infusion during induction of general anesthesia (e.g., severe aortic valve stenosis, coronary artery disease, or heart failure)\n* Patients who are unable to understand, read, and provide informed consent in German","45 Years",{"count":78,"type":21},446,"INTERVENTIONAL",[81],"NA","INDUCT-Multi is a multicenter randomized trial investigating whether continuous, compared to bolus, administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients.",[84],"Postinduction Hypotension",[86,87,88,89,90,91],"postinduction hypotension","non-cardiac surgery","norepinephrine","bolus","hypotension","continuous","2026-06-24",{"date":94,"type":36},"2026-06-29",{"date":96,"type":36},"2026-05-07",{"date":98,"type":21},"2026-12",{"name":42,"class":43},4,{"id":102,"slug":4,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":52,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":79,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":128,"locationsCount":44},"100638644","NCT07615530","Positive Expectation Effects on Early Emotional Processing","Inclusion Criteria:\n\n* Aged 18-35 years\n* Normal or corrected to normal vision\n* Signed declaration of consent\n* German speaking\n\nExclusion Criteria:\n\n* No informed consent\n* Current intake of central nervous system active drugs\n* Under influence of alcohol\n* BDI score above 12\n* Significant acute somatic or neurological diseases\n* History of psychiatric or neurological disorders\n* Acute nasal diseases or injuries\n* EEG data with strong artefacts or excessive movement will be excluded from analysis\n* If a participant does not believe in the treatment on the screening day, they will not be included for the main study days",true,"35 Years",{"count":109,"type":21},51,[81],"Insights into the mechanisms of expectation effects in the emotional domain can be invaluable for the development of potential therapeutic interventions for mood disorders. Recent findings demonstrate that positive expectations alone can induce a positivity bias on the behavioral and the neural level (Baker et al.,2022, Mostauli et al., 2025). This is intriguing given that antidepressant treatments, which have high placebo rates are reported to reduce a negativity bias commonly observed in depression.\n\nResearch on placebo analgesia has shown that both higher-order cognitive expectations and lower-level learning mechanisms, such as conditioning, play a key role in placebo effects. The role of such lower-level processes is particularly underexplored in affective placebo effects. Closing this gap is crucial, as the long-term modulation of the emotional system likely depends on cognitively less demanding, bottom-up processes shaped by learning and conditioning. This is particularly relevant in clinical populations, where cognitive resources may be limited, but there is an abundance of prior experiences (i.e., learning).\n\nThe present study therefore investigates how treatment expectations influence early psychophysiological processing of emotional stimuli. Beyond behavioral measures, we will directly assess early neural and attentional mechanisms using sensory event-related potentials (ERPs) and reflexive gaze shifts. By combining EEG and eye-tracking, we aim to identify early markers of expectation effects during emotional processing in healthy participants (N=44 plus 15% potential dropout, 50% women), who perform an emotion classification task. Emotional faces will be presented at varied levels of stimulus visibility (alpha transparency), allowing us to model perceptual sensitivity and response bias without inducing ceiling effects.\n\nTreatment expectation will be induced by verbal instructions using an established protocol (e.g. Baker et al., 2022, Mostauli et al., 2025). We hypothesize that positive expectations enhance mood and decrease reaction times paralleled by better accuracy. Further, we hypothesize that positive treatment expectation enhances gaze shifts toward the mouth region which is the primary diagnostic feature for happy faces. On the neural level we expect that positive expectations modulate EEG signal patterns associated with early emotional valence processing. Additionally, whole-brain and time-frequency analyses, as well as representational similarity analyses, are planned to further explore into neural expectation effects and potential changes in the hierarchical representation of emotional processing.",[113],"Positive Expectations",[115,116,117,118,119,120],"Treatment expectation","EEG","Eye Tracking","Emotional processing","Placebo","Positive expectation","NOT_YET_RECRUITING","2026-05-29",{"date":124,"type":36},"2026-06-02",{"date":126,"type":21},"2026-06",{"date":98,"type":21},{"name":42,"class":43},{"id":130,"slug":4,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":79,"phases":138,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":44},"100639133","NCT07600151","Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma","A Clinical Phase I\u002FII, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients","CONQUISTADOR","Inclusion Criteria:\n\n* Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.\n* Participants must have High-risk myeloma according to IMS\u002FIMWG CGS\n* Participants must be considered a candidate for high-dose chemotherapy and ASCT, as described in the protocol.\n* Participants must have measurable disease as defined in the protocol. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions).\n* Participants must have clinical laboratory values within a prespecified range.\n\nExclusion Criteria:\n\n* Known contraindications to the use of any IMP or axMP or required concomitant drugs or supportive treatment.\n* known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow), POEMS syndrome, Waldenstrom's macroglobulinemia; primary plasma cell leukemia\n* Administration of systemic therapy for multiple myeloma except osteoprotective therapy. Emergency myeloma treatment with dexamethasone is allowed according to specifications in the protocol. It is allowed to include patients after 1 cycle of any anti-myeloma first-line treatment within the specifications of the protocol\n* known central nervous system involvement by MM.",{"count":137,"type":21},220,[139,140],"PHASE1","PHASE2","This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.",[143,144],"Myeloma Multiple","Myeloma","2026-05-14",{"date":147,"type":36},"2026-05-20",{"date":149,"type":21},"2026-12-01",{"date":151,"type":21},"2036-12-31",{"name":42,"class":43},{"id":154,"slug":4,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":79,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100504871","NCT05853965","Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma","Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (Phase I\u002FIIa) The BELI(E)VE-Trial","BELI(E)VE","Relapsed and refractory t(11;14) Multiple Myeloma (RRMM)\n\nInclusion criteria:\n\n1. Subjects must be ≥ 18 years of age.\n2. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n3. Subjects must voluntarily sign and date an in-formed consent form\n4. Subjects must have had documented multiple myeloma requiring treatment as defined by the criteria below:\n\n   Monoclonal plasma cells in the bone marrow \\> 10% and\u002For presence of a biopsy proven plasmacytoma at some point in their disease history requiring treatment according diag-nostic criteria (IMWG updated criteria 2014, Rajkumar et al. 2014) with measurable dis-ease at screening (serum M-protein \\> 500 mg\u002FdL or urine M protein 200 mg\u002F24h, in case of oligosecretory MM serum free light chain \\> 10mg\u002FdL and abnormal kap-pa\u002Flambda free light chain ratio)\n5. Cytogenetics\u002FFISH confirming t(11;14)\n6. Prior treatment requirements:\n\n   Prior treatment requirements:\n\n   a. Subjects must have received at least 1 prior treatment line (induction, high-dose, consolidation and maintenance is considered as one treatment line). All patients have to have received at least one proteasome inhibitor and at least one immunomodulatory agent and at least one anti-CD38 monoclonal antibody.\n\n   b. Subjects must have documented evidence of progressive disease on or after the last treatment line.\n\n   c. Subjects with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met: i. ASCT was \\>100 days prior to initiating study treatment, and ii. No active bacterial, viral, or fungal in-fection(s) present.\n7. Subjects must have adequate organ function, defined as follows:\n\n   a. Hemoglobin ≥8.0 g\u002FdL (without transfusion of red blood cells for the past 14 days) b. Absolute neutrophil count ≥ 1.5 x109\u002FL (with-out growth factor support for the past 14 days) c. Platelet count more or equal 75 x109\u002FL (with-out growth factor or platelet stimulating agents for the past 14 days) d. Adequate hepatic function per local laborato-ry reference range as follows: i. Aspartate aminotransferase (AST) ≤ 2,5 x upper limit of normal (ULN); ii. Alanine aminotransferase (ALT) ≤ 2.5 x ULN iii. Total bilirubin ≤ 1.5 x ULN, except in subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bili-rubin ≤ 1.5 x ULN). Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C35%.\n\n   e. Subjects must have adequate renal function as demonstrated by eGFR ≥30 mL\u002Fmin\u002F 1.73 m2 as calculated by Modified Diet in Renal Disease (MDRD) formula f. Spot urine (albumin\u002Fcreatinine ratios (spot urine) \\\u003C500 mg\u002Fg (56 mg\u002Fmmol) OR Urine Dipstick Negative\u002Ftrace (if 1+ only eligible if confirmed \\\u003C500 mg\u002Fg (56 mg\u002Fmmol) by albumin\u002Fcreatinine ratio (spot urine from first void) g. Corrected serum calcium ≤ 14 mg\u002FdL (≤3,5 mmol\u002FL); or free ionized calcium ˂ 6,5 mg\u002FdL (˂1,6 mmol\u002FL)\n8. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n   1. Is not a woman of childbearing potential (WOCBP) OR\n   2. Is a WOCBP and using a contraceptive method that is highly effective\n9. Male participants are eligible to participate if they agree to the refrain from donating sperm and either bei abstinent from heterosexual intercourse or agree to use a highly effective contraceptive method during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm\n10. All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment.\n11. All subjects must agree not to share study medication.\n12. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be ≤ Grade 1 at the time of en-rolment except for alopecia.\n\nExclusion Criteria:\n\n1. Subject has received prior Venetoclax and\u002For anti BCMA treatment.\n2. Participant has used an investigational drug or approved systemic anti-myeloma therapy with-in 14 days or five half-lives, whichever is short-er, preceding the first dose of study drug. The only exception is emergency use of a short course of corticosteroids (equivalent of Dexa-methasone 40 mg\u002Fday for a maximum of 4 days) up to 7 days before treatment.\n3. Participant has had plasmapheresis or radia-tion therapy within 7 days prior to first dose of study treatment\n4. Participant has current corneal epithelial dis-ease except mild changes in corneal epitheli-um\n5. Participant has current unstable liver or biliary disease\n6. Participant has a presence of active renal con-dition (infection, requirement for dialysis or any other condition that could affect participant's safety).\n7. Participant has had major surgery ≤ 4 weeks prior to initiating study treatment. Kyphoplasty is not considered a major surgery.\n8. Participant must not use contact lenses while participating in this study. Bandage contacts may be prescribed by an eye care professional if needed.\n9. Participant has any evidence of active mucosal or internal bleeding or other gastrointestinal disease that may significantly alter the absorp-tion of oral drugs.\n10. Participant has evidence of cardiovascular risk as defined in the protocol\n11. Participant has known immediate or delayed hypersensitivity reaction or idiosyncratic reac-tions to IMPs or drugs chemically related to IMPs, or any of the components of the study treatment\n12. Participant has an invasive malignancy other than disease under study within 5 years before trial inclusion, except\n\n    * Adequately treated in situ carcinoma of the cervix uteri or the breast;\n    * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\n    * Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment;\n    * Previous malignancy with no current evi-dence of disease, and which was confined and surgically resected (or treated with other mo-dalities) with curative intent and unlikely to im-pact survival during the duration of the study.\n13. Participant is pregnant or lactating\n14. Participants who have had prior allogeneic stem cell transplant.\n15. Participants with symptomatic amyloidosis, ac-tive POEMS syndrome (polyneuropathy, or-ganomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes) or active plasma cell leukaemia at the time of screening.\n16. Participants with any serious and\u002For unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, ob-taining informed consent or compliance to the study procedures.\n17. Subject is known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B sur-face antigen (HBsAg) or antibodies to hepatitis B surface and core antigen (anti HBs and anti HBc respectively), or hepatitis C (anti-HCV an-tibody positive or HCV RNA quantitation posi-tive).\n18. Current immune or inflammatory conditions re-quiring immunosuppressive treatment (e.g. systemic lupus erythematosus, rheumatoid ar-thritis).\n19. Subject must not have received any live vac-cines within 8 weeks prior to first dose of study treatment.\n20. Subject must not use or anticipate the use of prohibited medications or foods during study participation.\n21. Subject does not have a history of or show any signs of known meningeal\u002Fcentral nervous sys-tem involvement by myeloma.\n22. Evidence of other clinically significant uncon-trolled condition(s) that is likely to interfere with the study proce-dures or results, or that in the opinion of the investigator, would constitute a hazard for the participation in this study.\n23. Subject is known or suspected of not being able to comply with the study protocol. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit or confound the pro-tocol-specified assessments.\n24. Treatment with any of the following within 7 days prior to the first dose of study drug:\n\n    1. moderate or strong cytochrome P450 3A (CYP3A) inhibitors\n    2. moderate or strong CYP3A inducers\n25. Administration or consumption of any of the fol-lowing within 3 days prior to the first dose of study drug:\n\n    1. grapefruit or grapefruit products\n    2. Seville oranges (including marmalade con-taining Seville oranges)\n    3. star fruit\n26. Participation in any other clinical trial (with the exclusion of observational studies)",{"count":161,"type":21},45,[139,140],"The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed\u002Frefractory multiple myeloma bearing the translocation t(11;14)",[165,166],"Multiple Myeloma","Multiple Myeloma in Relapse",[168,169,170,171],"t(11;14)","venetoclax","belantamab mafodotin","multiple myeloma",{"date":173,"type":36},"2026-05-18",{"date":175,"type":36},"2023-06-28",{"date":177,"type":21},"2028-12",{"name":42,"class":43},5,{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":79,"phases":188,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":44},"100461778","NCT05293080","Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE","EAST-STROKE","Inclusion Criteria:\n\n* Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis\n* Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable\n* AF first detected ≤1 year prior to randomization\n* Informed consent\n\nExclusion Criteria:\n\n* End-stage cancer or life-expectancy \\\u003C 12 months due to other advanced co-morbid illness\n* Prior AF ablation or surgical therapy of AF\n* Patients not suitable for rhythm control of AF due to cardiac conditions",{"count":187,"type":21},1746,[189],"PHASE3","This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.",[192,193],"Acute Ischemic Stroke","Atrial Fibrillation",[195,196,197,198,199],"Acute ischemic stroke","Atrial fibrillation","Rhythm control","Ablation","Antiarrhythmic drugs",{"date":173,"type":36},{"date":202,"type":36},"2025-11-06",{"date":204,"type":21},"2031-09",{"name":42,"class":43},{"id":207,"slug":4,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":79,"phases":216,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":4},"100639882","NCT07581171","Creating Encounters Between Generations - Together Instead of Alone (GemsE)","Creating Encounters: Generations in Action - Together Instead of Alone (GemsE)","GemsE","Inclusion Criteria:\n\n* Older adults aged 60 years and older who are residents of Hamburg\n* Children and adolescents aged 12 to 21 years with at least one parent with a mental illness and who are residents of Hamburg\n* Sufficient German language proficiency\n* Ability and willingness to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Children and adolescents with severe acute psychological symptoms requiring inpatient treatment, including acute suicidality, acute substance use, or acute psychotic symptoms\n* Older adults with acute psychological crises or untreated severe mental illness preventing reliable participation\n* Older adults with cognitive impairment or dementia preventing reliable participation in the intervention","12 Years",{"count":215,"type":21},80,[81],"Elderly people and children and young people (CYP) and from families with mentally ill parents are particularly affected by loneliness. The GemsE project is investigating whether intergenerational mentoring between seniors and children or young people helps to reduce loneliness and improve the mental well-being and quality of life of both groups. The aim of the study is to scientifically record the effect of these sponsorships and to find out how such encounters can be successfully organized.",[219,220,221],"Loneliness","Mental Well-being","Health-related Quality of Life",[223,224,225,226,227],"elderly people","children of parents with mental illness","loneliness","psychosocial health","intergenerational tandems","2026-05-06",{"date":230,"type":36},"2026-05-12",{"date":232,"type":21},"2026-06-01",{"date":149,"type":21},{"name":42,"class":43},{"id":236,"slug":4,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},"100415327","NCT04688190","CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry","Choice of Optimal Transcatheter Treatment for Mitral Insufficiency Registry","CHOICE-MI","Inclusion Criteria:\n\n* clinically significant mitral insufficiency\n* patient underwent screening for TMVI\n* echocardiography data at baseline (and after TMVI, E2E and surgery)\n* follow-up of at least 30 days\n\nExclusion Criteria:\n\n\\- age under 18 years",{"count":243,"type":21},1000,"This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice.\n\nPatients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical\u002Fconservative therapy.",[246,247,248],"Mitral Regurgitation","Mitral Valve Disease","Mitral Annular Calcification","2026-05-03",{"date":96,"type":36},{"date":252,"type":36},"2020-11-01",{"date":254,"type":21},"2030-12-31",{"name":42,"class":43},43,{"id":258,"slug":4,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":44},"100573028","NCT06740942","Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke","ARIADNE","Inclusion Criteria:\n\n* Diagnosis of either\n\n  * acute ischemic stroke with either an ischemic lesion visible on CT\u002FMRI or persistent focal deficits 24 hours after symptom onset, or\n  * Transient ischemic attack with transient clinical deficits including motor or speech disturbance and not restricted to isolated vertigo\u002Fdizziness, visual disturbance, or sensory disturbance.\n* symptom onset within 72h prior to hospital admission,\n* a pre-stroke\u002FTIA ability to walk without help from another person (modified Rankin scale score \\\u003C 4),\n* age \\> 18 years, and\n* informed consent by either the patient or a legal representative (including a spouse)\n\nExclusion Criteria:\n\n* In-hospital stroke,\n* contraindications to MR imaging (e.g., claustrophobia, pregnancy, pacemakers, implants),\n* known moderate to severe dementia,\n* previous structural brain damage (except leukoariosis due to cerebral small vessel disease),\n* hemodynamically relevant stenosis of the common or internal carotid artery, or\n* left heart failure with estimated left ventricular ejection fraction \\\u003C 50%,\n* concomitant systemic illness that can lead to dysautonomia, such as an active infection, thyroid disease, or neurodegenerative disorder (e.g. PD, MSA).",{"count":264,"type":21},100,"The goal of this observational study is to\n\n* to investigate the prevalence and time course of autonomic dysfunction in acute ischemic stroke patients;\n* to evaluate the influence of lesion location on autonomic dysfunction;\n* to identify patterns of structural and functional brain connectivity within the central autonomic control circuits associated with autonomic dysfunction; and\n* to explore causal models of the link between brain lesions; cardiac, immunological and endocrine biomarkers; and dysautonomia.\n\nResearchers will compare patients with acute ischemic stroke to patients with transient ischemic attacks to study the effect of acute ischemic brain lesions.\n\nParticipants will\n\n* undergo cardiovascular autonomic function testing;\n* receive structural and functional MR imaging;\n* provide blood samples for determinaton of serological biomarkers auf dysautonomia.",[192,267],"Transient Ischemic Attack",[269,270,271,272,273,274,275,276,277,278,279,280,281,282],"Autonomic dysfunction","cardiovascular dysregulation","brain-heart axis","stroke-heart syndrome","acute ischemic stroke","transient ischemic attack","autonomic function test","central autonomic network","network lesion mapping","lesion symptom mapping","resting-state fMRI","functional brain network","structural brain network","diffusion tensor imaging","2026-05-01",{"date":96,"type":36},{"date":286,"type":36},"2025-08-04",{"date":98,"type":21},{"name":42,"class":43},{"id":290,"slug":4,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":79,"phases":298,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":44},"100592449","NCT06993571","Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor","Closed-loop Phase-adaptive Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Activity in the Cerebello-thalamo-cortical Network to Reduce Parkinson's Disease Tremor","tACS_PD_TR","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's disease based on UK Brain Bank criteria\n* Patient exhibiting moderate to severe hand tremor\n* Provision written informed consent by the patient\n\nExclusion Criteria:\n\n* History of other neurological disorders such as vascular malformations, ischemic or haemorrhagic stroke, cerebral neoplasia, epilepsy, or major psychiatric illness\n* Existence of heart pacemaker or metal implants in the body\n* Pregnancy",{"count":297,"type":21},10,[81],"Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by different motor symptoms, including tremor, which is particularly difficult to manage. Common treatments, such as dopaminergic therapy, can have limitations in efficacy. Recent advancements in non-invasive brain stimulation, specifically phase-adaptive transcranial alternating current stimulation (tACS), offer a promising approach to reduce PD tremor. In the current project, a newly developed closed-loop system delivers precisely synchronized cerebellar tACS by aligning stimulation with the intrinsic hand tremor signal. The study will assess the efficacy of this novel approach to reduce hand tremor in PD patients.",[301,302],"Parkinson's Disease (PD)","Tremor",[304,305,306,307,308,309,310],"Parkinson's disease","Hand tremor","Transcranial alternating current stimulation","Non-invasive brain stimulation","Closed-loop stimulation","Phase-adaptive stimulation","Tremor entrainment","2026-04-28",{"date":313,"type":36},"2026-05-04",{"date":315,"type":36},"2025-04-16",{"date":317,"type":21},"2026-12-31",{"name":42,"class":43},{"id":320,"slug":4,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":79,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":44},"100587711","NCT06931938","Awake Prone Positioning in Spontaneous Breathing Patients With Acute Hypoxic Respiratory Failure Due to Pneumonia","Awake PROne Positioning in PatientS With Acute Hypoxemic Respiratory Failure in Germany - A Randomized Controlled Study","PROSA","Inclusion Criteria:\n\n* The focus of this trial is to treat patients with respiratory failure. The inclusion criteria are selected accordingly. Patients meeting all of the criteria listed below will be included in the study:\n\n  * Patients in the intensive care unit\n  * High possibility of Pneumonia (community-acquired pneumonia or hospital-acquired pneumo-nia) either diagnosed by chest x-ray or computed tomography or clinically diagnosed at least with one of the following signs\n\n    * Appearance of purulent secretions or changes in characteristics (color, odor, quantity, consistency)\n    * Cough or dyspnea or tachypnea\n    * Evocative auscultation\n  * Presence of acute hypoxemic respiratory failure (PaO2\u002FFIO2 ≤ 300 mmHg or SpO2\u002FFiO2 ≤ 315)\n\nExclusion Criteria:\n\n* Patients are excluded from the study if any of the following criteria are met at screening or before ran-domization, a detailed list is shown in the study manual:\n\n  * Age below 18\n  * Pregnant woman\n  * Patient is unlikely\u002Funable to awake prone positioning, or to be compliant as indicated by the treating team\n  * Prolonged need (≥ 4 days) for HFNO, NIV or CPAP before study inclusion\n  * Urgent need for endotracheal intubation\n  * Invasive Mechanical Ventilation\n  * Shock\n\n    o Defined as need for vasopressor ≥ 0.4 mcg\u002Fkg\u002Fmin to maintain a mean blood pressure of ≥ 65 mmHg or systolic blood pressure ≥ 90 mmHg\n  * Participation in another clinical interventional trial in the last 3 months\n  * Previous Participation in the PROSA Trial\n  * Long-term oxygenation therapy (LTOT) or continuous positive airway pressure (CPAP) therapy before hospital admission\n  * Treatment",{"count":327,"type":21},342,[81],"Prone positioning has shown beneficial effects in intubated patients with severe respiratory failure and positive effects in awake patients with COVID-19 pneumonia. Conclusive evidence for patients with AHRF without COVID-19 is still missing. The investigators hypothesis that awake prone position in patients with AHRF is superior to standard supine\u002Fsemi-recumbent position in terms of reducing the rate of tracheal intubation and\u002For all-cause death within 28 days after randomization.",[331],"Acute Hypoxemic Respiratory Failure",{"date":313,"type":36},{"date":334,"type":36},"2025-04-11",{"date":336,"type":21},"2027-06-30",{"name":42,"class":43},{"id":339,"slug":4,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":79,"phases":345,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":44},"100636325","NCT07564219","BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma","BEAM-MM","Inclusion Criteria:\n\n* Multiple Myeloma with indication for CAR-T cell therapy with Ciltacabtagene autoleucel (target antigen: BCMA) or a BCMA-directed bispecific antibody (e.g., Teclistamab, Elranatamab, Linvoseltamab).\n* Age ≥18 years on the day the informed consent is signed.\n\nExclusion Criteria:\n\n* Active infection requiring systemic therapy.\n* Known history of infection with Human Immunodeficiency Virus (HIV) or Hepatitis.\n* Significant short-term weight loss (\\>10% within the last 6 weeks).\n* ECOG Performance Status ≥2.\n* Prior immunoeffector cell therapy (CAR-T cell therapy or bispecific antibodies).\n* Active immunosuppression due to another condition (e.g., autoimmune disease, second malignancy).\n* Very high tumor burden with high risk for tumor lysis syndrome, as determined by myeloma-specific markers or markedly elevated LDH (per the treating myeloma team).\n* Women of childbearing potential in whom pregnancy cannot be reliably excluded prior to study entry.",{"count":161,"type":21},[81],"This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of immunotherapy in patients with multiple myeloma, while remaining safe and well-tolerated. Patients will be randomly assigned to one of four intervention groups or a control group. The intervention groups will either follow a ketogenic diet (less than 10% of calories from carbohydrates) or receive oral supplementation with deltaG® Ketone Monoester Performance \\[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate; CAS 1208313-97-6; TdeltaS Global, Inc., Oxford, UK\\], administered orally three times daily at either a low dose (13.5 g per serving, 40.5 g\u002Fday) or a high dose (25 g per serving, 75 g\u002Fday), in accordance with the FDA GRAS-approved dosing range. The control group will receive standard nutritional care. The study includes two parts: Part A enrolls patients receiving bispecific antibody treatment, and Part B enrolls patients receiving CAR-T cell therapy. Both dosing levels are applied in each part.",[348,349,350],"Multiple Myeloma (MM)","CAR T Cells","Bispecific Antibodies",[352,353],"Ketogenic Diet","beta-hydroxybutyrate (BHB)","2026-04-26",{"date":313,"type":36},{"date":357,"type":36},"2026-01-30",{"date":359,"type":21},"2028-12-31",{"name":42,"class":43},{"id":362,"slug":4,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":79,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":44},"100636352","NCT07564570","Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma","SPRINT - Short Moderate Physical Regime INtervention Directly Before ImmunoTherapy for Melanoma","SPRINT","Inclusion Criteria:\n\n* Histologically confirmed metastatic malignant melanoma with an indication for immunotherapy (Nivolumab and Ipilimumab).\n* The participant provides written informed consent for the study.\n* The participant is at least 18 years of age on the day the informed consent is signed.\n* No prior systemic anticancer therapy for metastatic disease (e.g., cytotoxic or targeted agents).\n* ECOG (Eastern Cooperative Oncology Group) performance status score of ≤ 2.\n* No physical impairment that would preclude participation in physical exercise.\n\nExclusion Criteria:\n\n* Major surgery within 2 weeks prior to the start of the study intervention, or participants who have not fully recovered from the effects of a previous surgery.\n* Participants with a diagnosed immunodeficiency, or those receiving chronic systemic corticosteroid therapy (at a dose greater than 10 mg prednisone equivalent per day), or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study medication.\n* Participants with an active infection requiring systemic therapy.\n* Participants with a known history of infection with human immunodeficiency virus (HIV) or hepatitis.",{"count":369,"type":21},40,[81],"The aim of this research project is to determine whether a short bout of physical exercise immediately before the start of immunotherapy (Nivolumab and Ipilimumab) is feasible and has a positive effect on the effectiveness of immunotherapy. It is known that short-term physical exercise leads to marked changes in the innate and adaptive immune system. These changes-specifically an increase in natural killer (NK) cells and cytotoxic T cells-are associated with a better response to immunotherapy.\n\nThe patient population selected for this study consists of patients with advanced-stage melanoma who are receiving Nivolumab and Ipilimumab.\n\nFirst, we aim to assess whether such an intervention is feasible in a large proportion of patients, as many patients experience disease-related and treatment-related side effects.\n\nSecondary objectives are to demonstrate that the exercise intervention positively influences the immune system and that this, in turn, leads to an improved response to therapy, thereby positively affecting patient survival, improving quality of life, and reducing treatment-related side effects.",[373],"Metastatic Melanoma",[375,376,377,378,379],"exercise","Immunotherapy","Melanoma","Nivolumab","Ipilimumab",{"date":313,"type":36},{"date":382,"type":36},"2025-11-14",{"date":359,"type":21},{"name":42,"class":43},{"id":386,"slug":4,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":391,"targetDuration":392,"studyType":22,"phases":4,"briefSummary":393,"conditions":394,"keywords":398,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":44},"100632069","NCT07508891","Characterisation of phenotYpes in aCute Heart faiLure patiEnts","CYCLE","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure.\n* Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation de to a different cause. Out-patients with acute heart failure are not included.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* No written informed consent.",{"count":243,"type":21},"10 Years","An observational cohort study to evaluate the benefit of functional parameters, radiomics and blood biomarkers to predict the outcome of patients with acute heart failure.",[395,396,397],"Acute Heart Failure","Decompensated Heart Failure","Cardiogenic Shock",[399,400,401,402,403,404,405,406],"cardiogenic shock","acute heart failure","heart failure","biomarker","biobank","cohort study","phenotyping","risk prediction","2026-03-30",{"date":409,"type":36},"2026-04-02",{"date":411,"type":36},"2019-03-01",{"date":254,"type":21},{"name":42,"class":43},{"id":415,"slug":4,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":79,"phases":423,"briefSummary":424,"conditions":425,"keywords":431,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":44},"100622551","NCT07385092","Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery","The Effect of Continuous Monitoring Versus Routine Spot-checks on Altered Vital Signs in Patients Recovering From Non-cardiac Surgery on Normal Wards: the \"COME ON, NOW!\" Trial","COME ON NOW","Inclusion Criteria:\n\nConsenting patients ≥45 years scheduled for elective non-cardiac (abdominal and thoracic) surgery with planned postoperative admission to a normal ward after an overnight stay in an advanced post-anesthesia care unit.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Pregnancy\n* Impossibility to perform continuous monitoring with the Radius VSM sensor (Masimo, Irvine, CA)\n* Atrial fibrillation\n* Patients designated Do Not Resuscitate, or are receiving end-of-life care",{"count":422,"type":21},264,[81],"The \"COME ON, NOW!\" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after admission to the normal ward.",[426,427,428,429,430],"Vital Sign Monitoring","Post Operative Complications","Non-cardiac Surgery","RCT","Anesthesiology",[432,433,434,435,436,437,90,438],"continuous vital signs","vital signs","vital sign monitoring","post-operative care","anesthesiology","anesthesia","post-operative complications","2026-02-27",{"date":441,"type":36},"2026-03-02",{"date":443,"type":36},"2026-02-24",{"date":317,"type":21},{"name":42,"class":43},{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":106,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":44},"100475124","NCT05466825","The Global Cardiovascular Risk Consortium","Predicting Cardiovascular Risk by Geographical Region and Sex Using Classical Cardiovascular Risk Factors","Inclusion Criteria:\n\nPopulation-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest.\n\nExclusion Criteria:\n\n* Participants with age below 18 years\n* No information on the outcome of interest\n* No information on the exposure of interest (CVD risk factors)\n* History of CVD at baseline",{"count":453,"type":21},3000000,"The Global Cardiovascular Risk Consortium (GCVRC) brings together harmonized individual-level data from currently more than 2 million (anticipated: approximately 3 million) individuals across 133 cohorts, 40 countries, and 6 continents, with recruitment ongoing. The GCVRC examines the impact of classical cardiovascular risk factors-such as body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes-on cardiovascular disease (CVD) and death from any cause worldwide.",[456,457],"All-cause Mortality","Cardiovascular Disease",[457,459,460,461,462,463,464,465,466],"Cardiovascular Risk Factors","Risk Factor Modification","Global","Lifetime Gain","Lifetime estimates","Projected risk reductions","Lifetime difference","Implementation strategies","2026-02-25",{"date":439,"type":36},{"date":470,"type":36},"2019-09-20",{"date":472,"type":21},"2028-06-30",{"name":42,"class":43},{"id":475,"slug":4,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":479,"targetDuration":481,"studyType":22,"phases":4,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":487,"leadSponsor":489,"locationsCount":4},"100627034","NCT07443384","Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus","Inclusion Criteria:\n\n* Board-certified in dermatology or plastic surgery,\n* At least five years of clinical experience using energy-based devices,\n* Documented experience of at least 5 years and\u002For publications related to RFMN\n\nExclusion Criteria:\n\n* not meeting inclusion critera",{"count":480,"type":21},30,"3 Months","Radiofrequency microneedling (RFMN) combines controlled delivery of radiofrequency energy into the dermis or subcutaneous tissue through arrays of insulated or non-insulated microneedles. This targeted thermal stimulation induces fibroblast (re-)activation leading to collagen remodeling and neocollagenesis, leading to clinical improvement in skin laxity and rhytides. Despite widespread clinical use, recent FDA announcements have highlighted concerns regarding potentially serious complications associated with RFMN treatments. Given this evolving landscape, consensus-based expert guidance is essential to support clinicians in navigating device selection, treatment parameters, patient counselling, and safety protocols. The present Delphi consensus aims to provide structured expert recommendations to address these emerging challenges.",[484],"Radiofrequency Microneedling",{"date":441,"type":36},{"date":283,"type":21},{"date":488,"type":21},"2026-10-01",{"name":42,"class":43},{"id":491,"slug":4,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":497,"targetDuration":498,"studyType":22,"phases":4,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":44},"100618980","NCT07338669","Hamburg Acute Renal Injury Study (HARIS)","Hamburg Acute Renal Injury Study","HARIS","Inclusion Criteria:\n\n* Hospitalized individuals with acute kidney injury (AKI), defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria or hospitalized individuals with acute illness who have not developed AKI (control group)\n* Age ≥ 18 years at time of enrollment\n* Personally signed informed consent\n\nExclusion Criteria:\n\n* None",{"count":243,"type":21},"1 Year","The Hamburg Acute Renal Injury Study (HARIS) is a prospective observational cohort study aimed at investigating the mechanisms, risk factors, and clinical determinants of acute kidney injury (AKI) trajectories and consequences.",[501,502],"Acute Kidney Injury","Acute Kidney Injury (AKI)",[501,504,505],"AKI","Prospective observational cohort study","2026-01-03",{"date":508,"type":36},"2026-01-14",{"date":510,"type":36},"2025-09-16",{"date":512,"type":21},"2030-09",{"name":42,"class":43},{"id":515,"slug":4,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":79,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":543},"100616987","NCT07312760","Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)","Existential Distress in Advanced Cancer: Pragmatic Randomized Controlled Trial of a Short-term Psychodynamic Psychotherapy (ORPHYS) Compared to Treatment as Usual (TAU)","Inclusion Criteria:\n\n* UICC stage III\u002FIV solid tumor or advanced hematological cancer\n* Physical condition at beginning of treatment sufficient for outpatient treatment\n* Existential distress due to at least one of the following concerns: loss of hope, demoralization, fear of the future, loneliness, death anxiety, sense of isolation, death wishes\n* Severity of distress: significant subjective distress and impairment in functioning\n\nExclusion Criteria:\n\n* Acute suicidality with concrete or impending intent to follow through (suicide plan)\n* diagnosis of a substance dependence, substance abuse, or psychotic disorder (exception: tobacco-related disorders)\n* Inability to adhere to a psychotherapeutic setting\n* Other current psychotherapeutic or psycho-oncological treatment according to TAU definition\n* Insufficient German to give informed consent and complete self-report questionnaires",{"count":521,"type":21},160,[81],"The psychological challenges faced by patients with incurable cancer and their caregivers include an uncertain future, fear of dying and uncontrollable suffering, grief, and loneliness. In a significant subgroup, this challenge is associated with significant fear and existential distress. This distress can manifest itself, for example, in the form of demoralization, a state of despair and hopelessness in which the possibilities for coping seem exhausted. Although open discussions about fears at the end of life are becoming increasingly important, little is known about how patients with high existential distress can best be supported to promote quality of life.\n\nThe aim of the study is to test the effectiveness of the newly developed individual psychotherapy ORPHYS (ShORt-term psychodynamic psychotherapy in serious PHYSical illness) in reducing existential distress. To this end, a randomly selected half of the participants who receive ORPHYS treatment will be compared with a second group who receive the standard routine psycho-oncological treatment TAU (Treatment As Usual). The level of distress caused by demoralization will be used for the comparison. A total of 160 patients with advanced cancer will be included in the study.\n\nDue to improved treatment options, life expectancy for advanced cancer has increased significantly. This means that patients and their families must deal with the existential tension between uncertainty and a focus on life. The treatment is intended to contribute to providing the best possible support for patients who suffer from uncertainty and fears at the end of life.",[525],"Advanced Cancer, Various, NOS",[527,528,529,530,531,532,533,534],"Advanced cancer","Psycho-Oncology","Psychodynamic Psychotherapy","Demoralization","End-of-life","Randomized Controlled Trial","Existential Distress","Psychological Intervention","2025-12-30",{"date":537,"type":36},"2025-12-31",{"date":539,"type":36},"2025-10-24",{"date":541,"type":21},"2027-12",{"name":42,"class":43},3,{"id":545,"slug":4,"hasResults":11,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":550,"targetDuration":552,"studyType":22,"phases":4,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":569},"100241140","NCT02417324","International HIT-MED Registry (I-HIT-MED)","International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumours","Inclusion Criteria:\n\n* all patients with above mentioned diagnosis of all ages (except for ependymoma WHO I°, pineal parenchymal tumour of intermediate differentiation and papillary tumour of the pineal region, who will be registered only if primary diagnosis was before the 18th birthday)\n* any localisation of the primary tumour\n* all clinical stages\n* First diagnosis after 01.01.2012\n* No inclusion into a prospective clinical trial for the same diagnosis, due to non-eligibility, national lack of trial approval, or individual refusal of participation.\n* Written informed consent for data transfer and tumour sample submission according to the laws of each participating country is necessary.\n* National and\u002F or local ethical committee approval according to the laws of each participating country is necessary.\n\nExclusion Criteria:\n\n* Registration in another clinical trial for the same diagnosis (relapse is defined as a second diagnosis).\n* Lack of valid ethical committee approval.",{"count":551,"type":21},500,"5 Years","The I-HIT-MED registry registers clinical of children and adults with medulloblastoma, ependymoma, pineal tumours, or choroid plexus tumours in Germany and other countries that fulfil national ethic requirements for participation in this registry. These tumours are rare diseases, and many patients are treated outside of clinical trials. The I-HIT-MED registry allows collection of data und biological material from those patients, and provides a basis for standard treatment recommendations and counselling. It aims to improve the international cooperation and the medical knowledge in these rare diseases. Within the I-HIT-MED registry, it is a goal to maintain and improve networks for quality assurance in national groups where they are already established, and to support the implementation in national groups, where there is no quality assurance network yet.",[555],"Childhood Brain Tumor",[557,558,559,560],"medulloblastoma","ependymoma","pineal tumour","CPT","2025-11-27",{"date":563,"type":36},"2025-12-04",{"date":565,"type":4},"2015-01",{"date":567,"type":21},"2029-12",{"name":42,"class":43},57,{"id":571,"slug":4,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":79,"phases":578,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":597,"locationsCount":44},"100608353","NCT07200453","Evaluation of an Interactive E-learning Environment to Enhance Digital Health Literacy in Cancer Patients","Development and Effectiveness Evaluation of an Interactive E-learning Environment to Enhance Digital Health Literacy in Cancer Patients: Study Protocol for a Randomized Controlled Trial","Inclusion criteria:\n\n* cancer diagnosis\n* sufficient knowledge of the German language as all study content and questionnaires will be in German only\n* Participants must also have and be able to use a digital device (smartphone, tablet, PC, laptop, etc.) with an internet connection\n* Confirm consent to participate in the study\n\nExclusion criteria:\n\n* Patients who are severely cognitively impaired due to their cancer or other illness\n* Patients who are unable to operate a digital device",{"count":577,"type":21},660,[81],"This study aims to create and test an online learning tool to help people with cancer improve their skills in finding and understanding health information online. The main question it aims to answer is:\n\n• Do people with cancer who use the online learning tool improve their skills more than those who don't use the tool?\n\nThe investigators will test this idea in a study. The investigators will put people into different groups by chance and compare the results. 660 people with cancer will participate. These people will be chosen to represent different types of cancer.\n\n* Group 1: Uses the online learning too (3 versions)\n* Group 2: Uses a PDF with the same information\n* Control Group: Receives no intervention\n\nWhat Participants Will Do:\n\nUse the online tool or PDF to learn how to find reliable cancer information online.\n\nAnswer questions about their digital health skills before starting, after 2 weeks, and after 8 weeks.\n\nDevelopment:\n\nBefore the start of the main study the online tool will be developed and tested. The investigators will first show a prototype of the tool to two discussion groups and use their feedback to improve it. Then, experts and people with cancer will test the final version",[581],"Neoplasms",[583,584,585,586,587,588,589,590],"digital health","eHealth","health literacy","eHealth literacy","health information","e-learning","medical education","digital health literacy","2025-09-28",{"date":593,"type":36},"2025-10-01",{"date":595,"type":36},"2025-01-16",{"date":593,"type":21},{"name":42,"class":43},{"id":599,"slug":4,"hasResults":11,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":11,"sex":16,"minAge":604,"maxAge":52,"enrollmentInfo":605,"targetDuration":4,"studyType":79,"phases":607,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":4},"100593675","NCT07009522","Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART)","HEART","Autistic adolescents will be included in the study, recruited from various departments of the Clinic for Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics at UKE, as well as from autism therapy centers. Eligible participants are adolescents aged 13 to 18 years who meet the criteria for a primary diagnosis of an autism spectrum disorder-including early childhood autism (ICD-10: F84.0), atypical autism (ICD-10: F84.1), and Asperger's syndrome (ICD-10: F84.5)-and who have sufficient knowledge of the German language. The diagnosis should be confirmed based on developmental history, the ADOS-2 assessment, and a clinical diagnosis from a specialized clinician. Additionally, only autistic adolescents exhibiting difficulties in emotion regulation (measured by the Emotion Regulation Inventory (EDI-SF), T-score ≥ 60) will be included. Exclusion criteria are: below-average cognitive abilities, IQ ≤ 85 (ICD-10: F70); lack of German language skills; or significant visual or hearing impairments that cannot be corrected. Furthermore, patients with severe neurological or psychiatric conditions (e.g., epilepsy, syndromic disorders with neuropsychiatric involvement, psychoses) or current acute suicidality, as assessed clinically, will be excluded.","13 Years",{"count":606,"type":21},21,[608],"EARLY_PHASE1","The study focuses on a group training program called HEART aimed at helping adolescents with Autism Spectrum Disorder improve emotional regulation. It will use a pilot trial to evaluate the program's feasibility and effectiveness. The findings aim to advance scientific understanding and support the development of effective, evidence-based interventions to strengthen psychosocial support for autistic adolescents.",[611],"Study Group","2025-09-22",{"date":614,"type":36},"2025-09-26",{"date":616,"type":21},"2026-01-15",{"date":618,"type":21},"2027-02-15",{"name":42,"class":43},{"id":621,"slug":4,"hasResults":11,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":627,"conditions":628,"keywords":632,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":44},"100601750","NCT07114549","External Validation of the MASCAN Score for the Classification of Difficult Mask Ventilation","Inclusion Criteria:\n\n* Patients who are scheduled for surgery with general anesthesia and require facemask ventilation and tracheal intubation after induction of anesthesia\n* Patients aged 18 years or older\n* Provided informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Required rapid sequence induction or other contraindications for facemask ventilation\n* Planned awake tracheal intubation\n* No consent given",{"count":626,"type":21},926,"The MASCAN Score is a prospectively developed objective classification for difficult facemask ventilation. This prospective observational study aims to externally validate the MASCAN score in patients undergoing general anaesthesia for surgical procedures and to determine the influence of different approaches and techniques, such as the timing of neuromuscular blocking agents and manual versus controlled facemask ventilation. A secondary aim is to determine the diagnostic value of visual assessments of the capnography curve. Another secondary aim of the study is to compare the assessment of the first attempt success during tracheal intubation between the airway operator and an independent observer.",[629,630,631],"Airway Management","General Anesthesia","Mask Ventilation",[633,634],"Airway management","Mask ventilation","2025-08-17",{"date":637,"type":36},"2025-08-21",{"date":639,"type":36},"2025-08-08",{"date":641,"type":21},"2026-01",{"name":42,"class":43},{"id":644,"slug":4,"hasResults":11,"nctId":645,"briefTitle":646,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":648,"enrollmentInfo":649,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":651,"conditions":652,"keywords":655,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":662,"locationsCount":44},"100601814","NCT07115394","EEG Measurements to Capture DBS-induced Electric Potentials","Inclusion Criteria:\n\n* Provision of written informed consent by the patient\n* Age 35 - 85\n* patient groups: Parkinson's disease, essential tremor, dystonia\n* \\>3 months after surgery for DBS\n\nExclusion Criteria:\n\nnone.","85 Years",{"count":650,"type":21},20,"To measure the electric fields induced by DBS (deep brain stimulation) on the scalp and to improve electric field simulations, the investigators will measure EEG (electroencephalography) measurements with high sampling rates (\\>100 kHz). The investigators hypothesize that we can improve electric field simulations of DBS by validating and calibrating the simulations based on EEG measurements at high sampling rates (\\>100 kHz).",[653,654],"Deep Brain Stimulation","Parkinson's Disease",[656,116,657],"deep brain stimulation","electric potential",{"date":637,"type":36},{"date":660,"type":36},"2025-07-11",{"date":317,"type":21},{"name":42,"class":43},""]